Dementia and Alzheimer Disease

The NeurologyLive dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.

Episode 43: Is Telehealth Here to Stay for Alzheimer Disease Care?

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jessica Zwerling, MD, MS.

Compounding Challenges: Conducting Clinical Trials in Alzheimer Disease

Recent Breakthroughs in the Treatment of Alzheimer Disease

Experts in the diagnosis and treatment of Alzheimer disease discuss the recent approval of aducanumab, its implications on the field, and other promising therapies and diagnostic technologies in development.

NeuroVoices: James Galvin, MD, MPH, on Location and Greenhouse Space Effects on Alzheimer Risk

NeuroVoices: Jessica Caldwell, PhD, on the Association of Genetics and Alzheimer Disease

The director of the Women’s Movement Prevention Center at Cleveland Clinic discussed her new study, and the current knowledge of the role genetics play in Alzheimer disease risk.

Eli Lilly Initiates Rolling Submission for Donanemab in Early Alzheimer Disease

October 26, 2021

Article

The company is planning to enroll patients in a phase 3 head-to-head study comparing donanemab to aducanumab (Aduhelm; Biogen) to assess superiority of brain amyloid clearance.

This Week on NeurologyLive — October 25, 2021

October 25, 2021

Article

Here's what is coming soon to NeurologyLive.

NeurologyLive Friday 5 — October 22, 2021

October 22, 2021

Article

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

Aducanumab’s Clinical Use in Alzheimer Disease Appears Limited Post-Approval

October 21, 2021

Article

Despite projections that aducanumab (Aduhelm; Biogen) would be widely adopted in clinical practice after its June 2021 approval, financial reports suggest a different story. Jessica Zwerling, MD, MS, and Lon Schnider, MD, MS, offered their perspectives on its clinical application thus far.

This Week on NeurologyLive — October 18, 2021

October 18, 2021

Article

Here's what is coming soon to NeurologyLive.

NeurologyLive Friday 5 — October 15, 2021

October 15, 2021

Article

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

ADMET 2 Trial Shows Positive Impact With Methylphenidate on Alzheimer Apathy

October 12, 2021

Article

Investigators observed a significant difference in the hazard ratio change on NPI apathy score within the first 100 days, suggesting an early treatment effect.

Gantenerumab Gets Breakthrough Designation for Alzheimer Following Significant Amyloid Reduction

October 11, 2021

Article

The pivotal phase 3 GRADUATE 1 and 2 trials will evaluate the effect of gantenerumab on amyloid load and downstream biomarkers of disease progression in patients with early Alzheimer disease.

This Week on NeurologyLive — October 11, 2021

October 11, 2021

Article

Here's what is coming soon to NeurologyLive.

Lack of Ethnic, Racial Diversity Identified in Alzheimer Disease Trial Cohorts

October 10, 2021

Article

Some of the most frequently reported trial criteria were the exclusion of participants with non-AD neurological disease, psychiatric illness, cardiovascular and cerebrovascular disease, obligated caregiver attendance, and cognitive impairment.